Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Sensorion SA ALSEN.PA
$0.29
+$0.02 (7.21%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
21583234.00000000
-
week52high
0.62
-
week52low
0.26
-
Revenue
4023497
-
P/E TTM
-1
-
Beta
2.04694600
-
EPS
-0.27000000
-
Last Dividend
0.00000000
-
Next Earnings Date
16 мар 2023 г. в 06:30
Описание компании
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Свежие комментарии
Свежие комментарии